Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study

详细信息    查看全文

• 作者：Jorge A. Marrero¹ ; ^{jorge.marrero@utsouthwestern.edu" class="auth_mail" title="E-mail the corresponding author} ; Masatoshi Kudo² ; Alan P. Venook³ ; Sheng-Long Ye⁴ ; Jean-Pierre Bronowicki⁵ ; Xiao-Ping Chen⁶ ; Lucy Dagher⁷ ; Junji Furuse⁸ ; Jean-Francois H. Geschwind⁹ ; Laura Ladró ; n de Guevara¹⁰ ; Christos Papandreou¹¹ ; Tadatoshi Takayama¹² ; Arun J. Sanyal¹³ ; Seung Kew Yoon¹⁴ ; Keiko Nakajima¹⁵ ; Robert Lehr¹⁶ ; Stephanie Heldner¹⁷ ; Riccardo Lencioni¹⁸
• 关键词：HCC ; hepatocellular carcinoma ; GIDEON ; Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib ; AE ; adverse event ; BCLC ; Barcelona Clinic Liver Cancer ; ECOG PS ; Eastern Cooperative Oncology Group performance status ; TNM ; tumor node metastasis ; CI ; confidence interval ; INR ; international normalized ratio
• 刊名：Journal of Hepatology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：65
• 期：6
• 页码：1140-1147
• 全文大小：787 K

文摘

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) is a prospective, observational registry study evaluating the safety of sorafenib and treatment practices in hepatocellular carcinoma patients. This large global database allowed for assessment of the use and tolerability of sorafenib in patients with liver dysfunction.

Methods

Baseline characteristics and medical/treatment history were collected in patients for whom a decision to treat with sorafenib had been made. Adverse event, dosing, and outcomes data were collected during follow-up.

Results

In the overall safety population (n = 3202), 1968 patients (61%) had Child-Pugh A status and 666 (21%) had Child-Pugh B. The majority of Child-Pugh A (72%) and Child-Pugh B (70%) patients received an initial sorafenib dose of 800 mg, consistent with the label, and dose reduction rates were 40% and 29%, respectively. The type and incidence of adverse events were generally consistent across Child-Pugh subgroups. The incidence of drug-related adverse events leading to discontinuation was similar between Child-Pugh A and Child-Pugh B patients (17% and 21%). In the intent-to-treat population (n = 3213), median overall survival (months [95% confidence interval]) was longer in Child-Pugh A patients (13.6 [12.8–14.7]) compared with Child-Pugh B patients (5.2 [4.6–6.3]).

Conclusions

In clinical practice, the safety profile of sorafenib appeared to be consistent across Child-Pugh A and Child-Pugh B patients. Findings suggest sorafenib may be safely used in some Child-Pugh B patients and indicate the importance of careful patient evaluation when making treatment decisions.

Lay summary

The GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) study is a large prospective registry of patients with liver cancer who were treated with sorafenib. The aims were to evaluate the safety and tolerability of sorafenib among those in which the liver was not functioning properly. The study showed that the safety profile of sorafenib was consistent across patients with preserved liver function and those in which the liver was not functioning properly, and therefore, suggesting that sorafenib may be a valid treatment for some patients with liver impairment.